Navigation Links
The Emerging Eastern European Market For Interventional Cardiology Devices Will Grow To $282 Million By 2021
Date:7/18/2013

TORONTO, July 18, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, markets for interventional cardiology (IC) devices have reached maturation in Belgium, Sweden, Switzerland and the Netherlands, while Eastern European markets will continue to see growth. Procedure volume growth will be slight in Belgium, Sweden, Switzerland and the Netherlands through 2021 because IC procedures are well accepted and have high adoption in these countries. In contrast, Eastern European markets, including the Czech Republic, Hungary, Poland and Romania will see higher growth in procedure volumes as the use of interventional cardiology becomes more widespread.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO)

Despite the European Union's attempts to harmonize prices, they will continue to differ greatly between countries. This has resulted in cross-border purchasing as facilities try to take advantage of lower device costs in neighboring countries. For example, a stent costs more than four times as much in the Czech Republic as it does in Poland, and therefore many Czech hospitals will engage in cross-border purchasing to combat high prices.

"Countries such as Romania, the Czech Republic, Hungary and Switzerland are seeing very high stent prices, especially for more advanced products such as drug-eluting stents (DES)," said MRG Senior Analyst Ian Swanson. "Many European governments are attempting to drive down prices by using group purchasing tactics such as those that have seen success in Germany. This makes devices more affordable to consumers and government payers, although it limits revenues for manufacturers competing in the European IC device market."

Falling prices will offset procedure volume growth in Belgium, Sweden, Switzerland and the Netherlands, and as a result, these markets will decline before stabilizing in 2018. Although prices will also decline in Eastern Europe, higher procedure volume growth will lead to modest market expansion through 2021.

Millennium Research Group's Eastern European Markets for Interventional Cardiology Devices 2013 and European Markets for Interventional Cardiology Devices 2013 (Part 2) reports include unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, accessory devices, intravascular imaging catheters and pressure guidewires in the Czech Republic, Hungary, Poland, Romania, Belgium, Sweden, Switzerland and the Netherlands. Supplemental country coverage is also available for Austria, Denmark, Finland, Greece, Norway, Poland, Portugal and Ukraine, as well as in aggregate for the rest of the European countries.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
2. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
3. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
4. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
5. Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
6. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
7. NextDocs Launches QuickStart for Emerging Growth Companies
8. Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
9. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
10. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
11. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology:
(Date:4/30/2016)... , ... April 30, 2016 , ... ... announced RANKED Health , a program to critically evaluate and rank health-focused ... of the program is to provide independent, unbiased and accurate information to help ...
(Date:4/30/2016)... ... 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick Wilson of ... Under the care of Maximized Living doctors at the London Olympics in 2012, ... Living is sending the largest contingent of elite chiropractors to Rio to support and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
Breaking Medicine News(10 mins):